# Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

> **NCT06866236** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Ebima Clifford Okundaye** · enrollment: 3000 (estimated)

## Conditions studied

- Chronic Kidney Diseases
- Acute Kidney Injury
- Kidney Failure

## Interventions

- **DRUG:** QRX-3

## Key facts

- **NCT ID:** NCT06866236
- **Lead sponsor:** Ebima Clifford Okundaye
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-10
- **Final completion:** 2027-07
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06866236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06866236, "Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06866236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*